Precautions for Elacestrant Use

Elacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive malignant tumors.

Precautions for Elacestrant Use

Dyslipidemia

Among patients receiving elacestrant, the incidences of hypercholesterolemia and hypertriglyceridemia are 30% and 27%, respectively. The incidences of grade 3 and 4 hypercholesterolemia and hypertriglyceridemia are 0.9% and 2.2%, respectively. Lipid profiles should be monitored regularly before the initiation of elacestrant therapy and during treatment.

Embryo-Fetal Toxicity

Based on animal study findings and its mechanism of action, elacestrant may cause fetal harm if administered to pregnant women. Pregnant women and women of childbearing potential should be informed of the potential fetal risks. Women of childbearing potential are advised to use effective contraceptive measures during elacestrant treatment and for 1 week after the last dose. Male patients with female partners of childbearing potential are also advised to use effective contraceptive measures during treatment and for 1 week after the last dose of elacestrant.

How to Detect ESR1 Mutations in Metastatic Breast Cancer?

Confirmation via Blood Test

A blood test prescribed by a physician can accurately identify the presence of ESR1 mutations. Even if testing has been performed previously, patients should discuss the need for retesting with their physician if the disease progresses, as metastatic breast cancer may undergo molecular changes over time.

Blood Test: The Gold Standard for ESR1 Mutation Detection

Blood test results help patients and their medical teams understand the causes of disease progression or the loss of efficacy of current therapies. Blood testing is the currently recommended standard method, rather than tissue biopsy—even a new biopsy is less accurate for detecting ESR1 mutations than a blood test.

Blood Test: Rapid, Accurate and Convenient

Results are typically available within approximately one week, and the test can effectively detect ESR1 mutations even in cases of multiple tumors, tumor heterogeneity, inaccessible tumor sites for sampling, or temporal changes in tumor characteristics. The test can be completed in a physician’s office or a clinical laboratory.

Open Communication with Your Medical Team About Treatment

Patients play a pivotal role in their own treatment journey. Actively participate in treatment decision-making and communicate openly and honestly with your medical team to ensure they fully understand your treatment goals and preferences. Understanding treatment expectations in advance and voicing your thoughts proactively will help optimize the therapeutic effect of elacestrant.

Key Questions About the Disease and Treatment Expectations

You may consult your medical team on the following:

Do I need to learn more about ESR1 mutations?

How long will I need to take elacestrant?

What therapeutic effects can I expect from elacestrant?

How to determine if elacestrant is suitable for me?

Key Questions About Treatment Process and Monitoring

You may ask about the following:

How should I document my treatment experience and side effects?

How often do I need to visit the clinic for monitoring and follow-up tests?

Key Questions About Follow-Up Care and Next Steps

You may inquire about the following:

When should I contact my physician or nurse immediately?

What information should I prepare or what preparations should I make before my next clinic visit?